摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-butyl-N-(2,6-dichlorobenzyl)-5-imidazo[1,2-a]pyridin-6-yl-1,3,4-thiadiazol-2-amine | 1311285-70-7

中文名称
——
中文别名
——
英文名称
N-butyl-N-(2,6-dichlorobenzyl)-5-imidazo[1,2-a]pyridin-6-yl-1,3,4-thiadiazol-2-amine
英文别名
N-butyl-N-[(2,6-dichlorophenyl)methyl]-5-imidazo[1,2-a]pyridin-6-yl-1,3,4-thiadiazol-2-amine
N-butyl-N-(2,6-dichlorobenzyl)-5-imidazo[1,2-a]pyridin-6-yl-1,3,4-thiadiazol-2-amine化学式
CAS
1311285-70-7
化学式
C20H19Cl2N5S
mdl
——
分子量
432.376
InChiKey
YYJQPIMRDBUDPR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.3
  • 重原子数:
    28
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    74.6
  • 氢给体数:
    0
  • 氢受体数:
    5

文献信息

  • [EN] NEW 2-AMINOTHIADIAZOLE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE 2-AMINOTHIADIAZOLE
    申请人:ALMIRALL SA
    公开号:WO2011069647A1
    公开(公告)日:2011-06-16
    The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or N-oxide thereof: wherein:. L represents a direct bond or a -S(O)2- group, • n is an integer having a value from 0 to 2, • R1 represents a pyridyl group or an imidazo[1,2-α]pyridinyl group, wherein the pyridyl group is substituted with one or more substituents selected from halogen atoms, a hydroxy group, a C1-4 alkyl group and a C1-4 alkoxy group, or • R1 represents a group of formula: wherein:. Ra and Rb independently represent a hydrogen atom, halogen atom or a linear or branched C1-4, alkyl group,. Rc represents a hydroxy group, a linear or branched C1-4 alkyl group or C1-4 alkoxy group wherein the alkyl and the alkoxy groups independently are optionally substituted with one or more substituents selected from hydroxy group, cyano group and-NR'R" groups and wherein R' represents a hydrogen atom or a linear or branched C1-4 alkyl group, R" represents a hydrogen atom or a linear or branched C1-4 alkyl group optionally substituted with a hydroxycarbonyl group; or R' and R" together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic ring optionally substituted with a hydroxycarbonyl group.. R2 represents a pyridyl group, a C3-6 cycloalkyl group or a phenyl group which is optionally substituted with one or more substituents selected from halogen atoms, cyano group, and C1-4 alkoxy group; and. R3 represents a C3-6 cycloalkyl group, a C3-6 cycloalkyl-C1-2 alkyl group or a linear or branched C2-4 alkyl group optionally substituted with one or more substituents selected from halogen atoms and C1-2 alkoxy group.
    本发明涉及一种具有如下式(I)的化合物,或其药学上可接受的盐或N-氧化物:其中:L代表直接键或-S(O)2-基团,n是一个取值范围为0至2的整数,R1代表吡啶基或咪唑[1,2-α]吡啶基,其中所述吡啶基被一个或多个卤素原子、一个羟基、一个C1-4烷基基团和一个C1-4烷氧基团中的一种或多种取代基取代,或R1代表如下式的基团:其中:Ra和Rb独立地代表氢原子、卤素原子或线性或支链的C1-4烷基基团,Rc代表一个羟基、一个线性或支链的C1-4烷基基团或C1-4烷氧基团,其中烷基和烷氧基基团可以独立地被一个或多个羟基、基和-NR'R"基团中的一种或多种取代基取代,其中R'代表氢原子或线性或支链的C1-4烷基基团,R"代表氢原子或线性或支链的C1-4烷基基团,可选地被一个羟基羰基基团取代;或R'和R"与它们连接的氮原子一起形成一个4至6成员的饱和杂环环,可选地被一个羟基羰基基团取代。R2代表吡啶基、一个C3-6环烷基基团或一个苯基,可选地被一个或多个卤素原子、基和C1-4烷氧基中的一种或多种取代基取代;R3代表一个C3-6环烷基基团、一个C3-6环烷基-C1-2烷基基团或一个线性或支链的C2-4烷基基团,可选地被一个或多个卤素原子和C1-2烷氧基中的一种或多种取代基取代。
  • New 2-aminothiadiazole derivatives
    申请人:Almirall, S.A.
    公开号:EP2343287A1
    公开(公告)日:2011-07-13
    The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or N-oxide thereof: wherein: • L represents a direct bond or a -S(O)2- group, • n is an integer having a value from 0 to 2, • R1 represents a pyridyl group or an imidazo[1,2-a]pyridinyl group, wherein the pyridyl group is substituted with one or more substituents selected from halogen atoms, a hydroxy group, a C1-4 alkyl group and a C1-4 alkoxy group, or • R1 represents a group of formula: wherein: o Ra and Rb independently represent a hydrogen atom, halogen atom or a linear or branched C1-4 alkyl group, o Rc represents a hydroxy group, a linear or branched C1-4 alkyl group or C1-4 alkoxy group wherein the alkyl and the alkoxy groups independently are optionally substituted with one or more substituents selected from hydroxy group, cyano group and-NR'R" groups and wherein ■ R' represents a hydrogen atom or a linear or branched C1-4 alkyl group, ■ R" represents a hydrogen atom or a linear or branched C1-4 alkyl group optionally substituted with a hydroxycarbonyl group; or ■ R' and R" together with the nitrogen atom to which they are attached form a 4 to 6 membered, saturated heterocyclic ring optionally substituted with a hydroxycarbonyl group. • R2 represents a pyridyl group, a C3-6 cycloalkyl group or a phenyl group which is optionally substituted with one or more substituents selected from halogen atoms, cyano group, and C1-4 alkoxy group; and • R3 represents a C3-6 cycloalkyl group, a C3-6 cycloalkyl-C1-2 alkyl group or a linear or branched C2-4 alkyl group optionally substituted with one or more substituents selected from halogen atoms and C1-2 alkoxy group.
    该发明涉及以下式(I)的化合物,或其药学上可接受的盐或N-氧化物: 其中: • L代表直接键或-S(O)2-基团, • n是一个整数,其值为0到2, • R1代表吡啶基或咪唑[1,2-a]吡啉基团,其中吡啶基被一个或多个取代基取代,所述取代基选自卤原子、羟基、C1-4烷基和C1-4烷氧基,或 • R1代表以下式的基团: 其中: o Ra和Rb独立地代表氢原子、卤原子或线性或支链的C1-4烷基, o Rc代表羟基、线性或支链的C1-4烷基或C1-4烷氧基,其中烷基和烷氧基独立地可以选择性地被一个或多个取代基取代,所述取代基选自羟基、基和-NR'R"基团,其中 ■ R'代表氢原子或线性或支链的C1-4烷基, ■ R"代表氢原子或选择性地被羟基羰基基团取代的线性或支链的C1-4烷基;或 ■ R'和R"与它们连接的氮原子一起形成一个4到6成员的饱和杂环环,该环可以选择性地被羟基羰基基团取代。 • R2代表吡啶基、C3-6环烷基基团或苯基,所述苯基可以选择性地被一个或多个取代基取代,所述取代基选自卤原子、基和C1-4烷氧基;和 • R3代表C3-6环烷基基团、C3-6环烷基-C1-2烷基基团或线性或支链的C2-4烷基基团,所述烷基基团可以选择性地被一个或多个取代基取代,所述取代基选自卤原子和C1-2烷氧基。
查看更多

同类化合物

苯甲醇,2-甲基-a-[1-(甲基氨基)环戊基]- 甲基5-氧亚基-4,5-二氢吡唑并[1,5-A]嘧啶-2-甲酸基酯 溴-6-甲基[1,2,4]噻唑并[1,5-a]吡啶 乙基[1,2,4]三唑并[1,5-a]吡啶-2-羧酸酯 三(二甲基氨基)(3H-1,2,3-三唑[4,5-b]吡啶-3-基氧代)膦六氟磷酸盐 [1,2,4]噻唑并[4,3-a]吡啶-7-胺 [1,2,4]噻唑并[4,3-a]吡啶-3-羧酸 [1,2,4]噻唑并[1,5-a]吡啶-8-胺 [1,2,4]噻唑并[1,5-a]吡啶-6-羧酸甲酯 [1,2,4]噻唑并[1,5-a]吡啶-6-羧酸 [1,2,4]噻唑并[1,5-a]吡啶-6-甲腈 [1,2,4]噻唑并[1,5-a]吡啶-6-甲胺 [1,2,4]噻唑并[1,5-a]吡啶-5-羧醛 [1,2,4]噻唑并[1,5-a]吡啶-5-羧酸甲酯 [1,2,4]噻唑并[1,5-a]吡啶-2-羧醛 [1,2,4]三氮唑[1,5-A]吡啶-6-甲醛 [1,2,4]三唑并[4,5-a]吡啶-3-磺酰胺 [1,2,4]三唑并[4,3-a]吡啶-5-羧酸 [1,2,4]三唑并[4,3-a]吡啶-5-硫醇 [1,2,4]三唑并[4,3-A]吡啶-8-胺 [1,2,4]三唑并[4,3-A]吡啶-8-羧酸 [1,2,4]三唑并[4,3-A]吡啶-7-胺 [1,2,4]三唑并[4,3-A]吡啶-7-羧酸 [1,2,4]三唑并[1,5-a]吡啶-7-羧酸 [1,2,4]三唑并[1,5-a]吡啶-6-胺 [1,2,4]三唑并[1,5-a]吡啶-5-羧酸 [1,2,4]三唑并[1,5-a]吡啶 [1,2,4]三唑并[1,5-A]吡啶-7-羧酸甲酯 [1,2,4]三唑并[1,5-A]吡啶-7-硼酸 [1,2,4]三唑[4,3-A]嘧啶-6-羧酸 [1,2,4]三唑[4,3-A]吡啶-3-硫醇 [1,2,4]三唑[1,5-a]吡啶-2-甲酸 [1,2,3]三唑并[1,5-a]吡啶-7-甲醛 [1,2,3]三唑并[1,5-a]吡啶-7-甲酰胺 [1,2,3]三唑并[1,5-a]吡啶-3-甲酰胺 [1,2,3]三唑并[1,5-a]吡啶-3-甲酰氯 N-羟基-7-氮杂苯并三氮唑 N-[5-[(1-甲基乙基)氨基]-7-(三氟甲基)[1,2,4]三唑并[1,5-a]吡啶-2-基]-3-吡啶甲酰胺 N-[5-(环丙基氨基)-7-(三氟甲基)[1,2,4]三唑并[1,5-a]吡啶-2-基]-3-吡啶甲酰胺 N,N-二乙基-7-硝基-1H-1,2,3-三唑并[4,5-c]吡啶-1-乙胺 GLPG-0634 中间体 ALK4/ALK5抑制剂 9-环戊基-7-乙基-3-(2-噻吩基)-6,9-二氢-5H-吡唑并[3,4-c][1,2,4]三唑并[4,3-A]吡啶 8-硝基[1,2,4]三唑并[4,3-a]吡啶 8-硝基[1,2,4]三唑并[1,5-a]吡啶 8-甲氧基-[1,2,4]噻唑并[1,5-a]吡啶-2-胺 8-甲氧基-5-碘-[1,2,4]噻唑并[1,5-a]吡啶-2-胺 8-甲基-[1,2,4]三唑并[1,5-A]吡啶 8-甲基-1,2,4噻唑并1,5-a吡啶-2-胺 8-溴2-甲基-[1,2,4]噻唑并[1,5-a]吡啶